B-cell depletion

Uplizna (inebilizumab-cdon) works to treat people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether such patients carry genetic variants linked to poor responses to other B-cell depleting therapies, new trial data show. An analysis of N-MOmentum Phase 2/3 data found that the approved therapy was as effective…

Uplizna (inebilizumab-cdon) was just as safe and effective in people with neuromyelitis optica spectrum disorder (NMOSD) treated after only one symptomatic attack as those treated after two or more attacks, according to an analysis of N-MOmentum Phase 2/3 trial data. This sub-analysis had sought to understand how a…

Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued to experience attacks after being treated with the therapy during the N-MOmentum Phase 2/3 clinical trial, recent data analysis shows. The data also demonstrated lower levels of key disease-related biomarkers,…

Treatment with Horizon Therapeutics’ Uplizna (inebilizumab) leads to a rapid and sustained drop in immune B-cells in adults with neuromyelitis optica spectrum disorder (NMOSD), data from the N-MOmentum Phase 2/3 clinical trial show. Notably, while all Uplizna-treated patients experienced significant clinical benefits, those with greater B-cell depletion showed lower…